CAMP4 Therapeutics Corporation Common Stock (CAMP)

Price$4.11

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)0.23%

Price vs S&P 500 (4W)-7.84%

VGM Score56.40

Market Capitalization$213.42M

All Metrics

Book Value / Share (Quarterly)$0.60

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-2.86%

Cash Flow / Share (Quarterly)$-0.51

Price vs S&P 500 (YTD)-41.11%

Gross Margin (TTM)35.78%

Net Profit Margin (TTM)-7.27%

EPS (TTM)$-2.24

10-Day Avg Trading Volume0.07M

EPS Excl Extra (TTM)$-2.24

Revenue Growth (5Y)-4.22%

EPS (Annual)$-2.65

ROI (Annual)-168.55%

Gross Margin (Annual)36.96%

Net Profit Margin (5Y Avg)-7.07%

Cash / Share (Quarterly)$1.91

Revenue Growth QoQ (YoY)-15.26%

ROA (Last FY)-68.25%

Revenue Growth TTM (YoY)5.57%

EBITD / Share (TTM)$-1.28

ROE (5Y Avg)-18.64%

Operating Margin (TTM)-5.42%

Cash Flow / Share (Annual)$-0.57

P/B Ratio6.91x

P/B Ratio (Quarterly)7.41x

Net Income / Employee (Annual)$-1,675,100

Net Interest Coverage (TTM)-1.91x

ROA (TTM)-95.64%

EPS Incl Extra (Annual)$-2.65

Current Ratio (Annual)7.35x

Quick Ratio (Quarterly)6.12x

3-Month Avg Trading Volume0.15M

52-Week Price Return120.97%

Revenue / Employee (TTM)$450,310,600,000

Tangible BV / Share (Quarterly)$-2.90

P/S Ratio (Annual)0.05x

Asset Turnover (Annual)0.76x

52-Week High$7.75

Operating Margin (5Y Avg)-1.59%

EPS Excl Extra (Annual)$-2.65

CapEx CAGR (5Y)5.89%

26-Week Price Return8.16%

Quick Ratio (Annual)7.31x

13-Week Price Return-10.46%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.15x

Enterprise Value$114.21M

Revenue / Share Growth (5Y)-4.22%

Asset Turnover (TTM)0.79x

Book Value / Share Growth (5Y)-41.47%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)8.82x

Pretax Margin (Annual)-10.63%

Cash / Share (Annual)$2.11

3-Month Return Std Dev121.69%

Gross Margin (5Y Avg)39.45%

Net Income / Employee (TTM)$-1,797,900

EBITDA CAGR (5Y)-30.38%

EBITDA Interim CAGR (5Y)-22.29%

ROE (Last FY)-168.55%

Net Interest Coverage (Annual)-2.83x

EPS Basic Excl Extra (Annual)$-2.65

Receivables Turnover (TTM)3.97x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.24

Receivables Turnover (Annual)4.08x

ROI (TTM)-194.57%

P/S Ratio (TTM)0.05x

Pretax Margin (5Y Avg)-5.59%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$-2.85

Free OCF CAGR (5Y)8.13%

Price vs S&P 500 (52W)96.60%

EPS Growth TTM (YoY)47.80%

Year-to-Date Return-32.95%

5-Day Price Return1.73%

EPS Normalized (Annual)$-2.65

ROA (5Y Avg)-4.61%

Net Profit Margin (Annual)-11.02%

Month-to-Date Return-6.38%

Cash Flow / Share (TTM)$0.03

EBITD / Share (Annual)$-1.68

Operating Margin (Annual)-8.83%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-5.86%

LT Debt / Equity (Quarterly)2157.89x

EPS Basic Excl Extra (TTM)$-2.24

P/B Ratio (Annual)6.67x

Inventory Turnover (TTM)7.17x

Pretax Margin (TTM)-6.83%

Book Value / Share (Annual)$0.92

Price vs S&P 500 (13W)-18.71%

Beta-22.97x

Revenue / Share (TTM)$7.92

ROE (TTM)-194.74%

52-Week Low$1.30

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.32est. -0.21

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.25

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
CAMPCAMP4 Therapeutics Corporation Common Stock	—	C	B	$4.11
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Camp4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-based therapeutics to restore protein levels in genetic diseases of the central nervous system and liver. The company's pipeline includes two lead programs, CMP-CPS-001 and CMP-SYNGAP.